BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
2725185
Number of visits today
1297
Number of downloads
1996279
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Scheen AJ. Could metformin modulate cardiovascular outcomes differently with DPP-4 inhibitors compared with SGLT2 inhibitors? Diabetes Metab 2021;47:101209. [PMID: 33189895 DOI: 10.1016/j.diabet.2020.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Scheen AJ. Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: a comprehensive review ranging from sulphonylureas to SGLT2 inhibitors. Diabetes & Metabolism 2022. [DOI: 10.1016/j.diabet.2022.101405] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chen SY, Kong XQ, Zhang KF, Luo S, Wang F, Zhang JJ. DPP4 as a Potential Candidate in Cardiovascular Disease. J Inflamm Res 2022;15:5457-69. [PMID: 36147690 DOI: 10.2147/JIR.S380285] [Reference Citation Analysis]
3 Scheen AJ. Antidiabetic agents and risk of atrial fibrillation/flutter: a comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes & Metabolism 2022. [DOI: 10.1016/j.diabet.2022.101390] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Wang D, Liu J, Zhou L, Zhang Q, Li M, Xiao X. Effects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites. Front Endocrinol 2022;13:905171. [DOI: 10.3389/fendo.2022.905171] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345